肿瘤标记物CA199、CEA和CA125在胰腺癌诊断中的价值

Values of CA199、CEA and CA125 in diagnosis of pancreatic carcinoma

目的:探讨CA199、癌脉抗原(CEA)、CA125及其联合检测对胰腺癌的诊断意义。方法:30例胰腺癌患者,男女各15例,年龄(56.4±8.2)岁;同期住院的胆囊息肉患者30例,男女各15例,年龄(52.1±7.6)岁。采用放射免疫分析法测定上述指标,并进行统计分析。结果:胰腺癌组血清CA199、CEA含量与对照组血清CA199、CEA有显著性差异(P<0.01,P<0.05),胰腺癌患者阳性率分别为83.3%,46.7%;胰腺癌组血清CA125含量与对照组血清CA125无显著性差异(P>0.05);CA199、CEA联合检测总阳性率可达96.7%。结论:CA199、CEA联合检测有利于胰腺癌的临床诊断。

Objective： To investigate the value of combined detection of CA199, CEA and CA125 in diagnosis of pancreatic carcinoma. Methods： The serum levels of CA199, CEA and CA125 in 30 cases of pancreatic cancer and 30 cases control group were detected and statistically analyzed. Results. Serum CA199. CEA level in pancreatic cancer patient were significantly higher than those in control group（ P 〈 0.01, P 〈 0.05 ）. There were no significant difference between pancreatic cancer group and control group in the level of Serum CA125 （ P 〉 0.05 ）. The positive rate could increased to 96.7% by combined test of serum CA199, CEA. Conclusion： Combined test of serum CA199 and CEA is a valuable method in diagnosis of pancreatic carcinoma.